Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade F 3.66 0.00% 0.00
DVAX closed unchanged on Friday, July 19, 2019, on 38 percent of normal volume.

Earnings due: Aug 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DVAX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Narrow Range Bar Range Contraction -3.43%
BB Squeeze Ended Range Expansion -3.43%
Fell Below 20 DMA Bearish -5.67%
Bollinger Band Squeeze Range Contraction -5.67%
BB Squeeze Started Range Contraction -5.67%

Older signals for DVAX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Health Biopharmaceutical Pharmaceutical Industry Asthma Astrazeneca Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Treatment Of Autoimmune And Inflammatory Diseases Novel Products Tlr7 Tlr9
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.85
52 Week Low 3.4
Average Volume 1,513,455
200-Day Moving Average 8.5093
50-Day Moving Average 4.7064
20-Day Moving Average 3.8795
10-Day Moving Average 3.832
Average True Range 0.2954
ADX 20.07
+DI 21.1548
-DI 28.8222
Chandelier Exit (Long, 3 ATRs ) 3.7438
Chandelier Exit (Short, 3 ATRs ) 4.2862
Upper Bollinger Band 4.2037
Lower Bollinger Band 3.5553
Percent B (%b) 0.16
BandWidth 16.713494
MACD Line -0.2186
MACD Signal Line -0.258
MACD Histogram 0.0394
Fundamentals Value
Market Cap 200.71 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -1.51
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.87
Resistance 3 (R3) 3.86 3.78 3.84
Resistance 2 (R2) 3.78 3.73 3.79 3.82
Resistance 1 (R1) 3.72 3.69 3.73 3.73 3.81
Pivot Point 3.64 3.64 3.65 3.65 3.64
Support 1 (S1) 3.58 3.59 3.59 3.59 3.51
Support 2 (S2) 3.50 3.55 3.51 3.50
Support 3 (S3) 3.44 3.50 3.49
Support 4 (S4) 3.45